Continuing our end-of-year review, we’ll take a moment to update Small Pharma’s last 12 months.
Last week, we reported that DMT-development firm Small Pharma had moved its lead candidate drug further through the clinical trial process with the completion of its Phase 2a trial. Small Pharma CEO says that results from this Phase 2a trial will be released in early Q1 — a significant milestone for the company and the industry.
Despite Small Pharma being a relatively, hmmm, small firm, the completion of a Phase 2a trial makes them one of the most advanced companies in terms of clinical trial development. From CEO George Tziras:
We look forward to sharing the SPL026 Phase IIa results very soon, as well as making progress throughout the year with additional SPL026 trials, and the first-in-human trial with SPL028, our novel deuterated DMT candidate.
In line with this significant progress across our portfolio, we look forward to continuing to expand internationally and growing our team as we prepare for a multi-site Phase IIb trial.
Some other highlights from Small Pharma in 2022:
- Completion of Phase IIa trial for lead product candidate SPL026, with supportive therapy for the treatment of Major Depressive Disorder
- SSRI drug interaction study initiated
- MHRA approval for new SPL026 trial
- Cash on hand as of August 31, 2022, was $27.1 million
- 2nd US patent granted for DMT products, the twelfth granted patent in its psychedelic and non-psychedelic portfolio, with over 70 pending applications)
- Received approval for Phase I Clinical Trial with SPL028, injectable deuterated DMT candidate with multi-layered IP protection
For more on Small Pharma, see the company’s video below and Small Pharma Gets Big Price Target From Two Analysts
